Invesaro

Stocks Health care PBLS

NASDAQ · Health care

Parabilis Medicines, Inc. (PBLS)

At June 30, 2026 it held $1.1B in cash against $6.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Parabilis Medicines, Inc. does

Parabilis Medicines, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBLS.

Latest SEC filings

What Parabilis Medicines, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 15, 2026
  2. September 2, 2026
  3. August 25, 2026
  4. August 14, 2026
  5. August 13, 2026
    Quarterly report 10-Q · period to June 30, 2026
  6. August 13, 2026
  7. August 6, 2026
  8. June 18, 2026
  9. June 11, 2026
  10. June 10, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 25, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PBLS

What does Parabilis Medicines, Inc. do?

Parabilis Medicines, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PBLS.

When did Parabilis Medicines, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 15, 2026.

Similar companies

Follow PBLS

Get an email when Parabilis Medicines, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PBLS: get an email when it files

Where the numbers come from

Financial figures are the values Parabilis Medicines, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.